Bristol Myers Is Very Focused on M&A, CEO Says

The transcript discusses Bristol Myers Squibb's growth strategy, focusing on launching new medicines and expanding their pipeline. The company expects significant revenue from these launches despite potential patent losses. The impact of COVID-19 on healthcare and business operations is addressed, highlighting the company's resilience. The discussion also covers FDA approvals and the regulatory process, emphasizing the importance of innovation and collaboration for future growth.

How has the FDA's interaction with Bristol Myers Squibb changed in recent years?

What role has digital data technology played in the development of new medicines?

What is the significance of the collaborations Bristol Myers Squibb has ongoing?